Pasireotide for Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

We are studying whether pasireotide can help patients with specific cancers live longer without their disease progressing. This trial focuses on those with synovial sarcoma and desmoplastic small round cell tumor.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Pasireotide
Pasireotide is a substance that lowers excess hormone production from certain pituitary tumors, used for Cushing's disease and acromegaly.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Universitaetsklinikum Essen AöR
Pädiatrische Hämatologie und Onkologie
Essen, Germany
Universitaetsklinikum Heidelberg AöR
National Center for Tumor Diseases (NCT)
Heidelberg, Germany
Klinikum Der Landeshauptstadt Stuttgart gKAöR
Tumorzentrum Eva-Mayr-Stihl
Stuttgart, Germany

Sponsor: Universitaetsklinikum Heidelberg AöR
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.